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Macintosh computer. Renal nerves were isolated and placed on bipolar electrodes and its activity 
measure~ using the above system. Saline (0. 9%. w /v N~Cl) ._was, jnfused , at 3 ml and the 
experiment began. 2h later~ .. F~II.9wing·fu.~. ~ollectiqn :of b_aseline dat?:~ bolus_ do~~:· rilmenidine, 
100, 300 ·~and} bOQ,' nig/kg \ye'fe·-a9~ip~t~ie~ .~n~ ::tl:t~ ·.sa1Jr1e Jnfu.~i§n via~:·:''. rease9; 'such that 
the anjmal.receivea·0.'25%'hody ·weight/min over'~4Q min~:and.blocks·. re_corairig were ma:de 
eve 5 tnih fo~ ·~·:·1urhe ex --~> ~·fori tr~atid "fifand:en~t:r·~~m· ~A:p;~~ ;' ,~ a--~a~R.s~· Wet~ recorded. · Therydat~~bb~~J1itJ~~,-·:t~~~red~~n~T2~~~,,;~1\NcivArct1r~~:;,,.~e~~ct~f~:~to~:be':$1 nificant 
(p<O. os).~ji:;~~-,~tf:11~f/ett~~,.;:~:~~<-~:1~;t~:P:~f: .. :'f:~·-~~!.;~~t~-~~;:~~;l/Ii\~)~if.·~~t~~~~~~lt~{~·~··~· 9 
The ·reslllts 'obtained demonstrated that at.al .·. SeS' of. rilrrt'enidine .there were decreases 
in the S~P-fn:·.?8tf.r.:!~g~ps:7.'?t~mf~i:il?·.\~-~imi .. ~~ ~!~~~~if1~:yja{~£s~iY~d fo·~-~Q~~~~t all .doses 
in the s.~~s~:~ut .oniY,:'at do~es.·aJ>oye :~90 .... g/kg_·I£?: ··fh~ lPSii~?~,tJiR~-M'as_decr:f?<:lS~d at doses 
of more··thc3fi;~300 ·mg/kg in,:D$HB.s·· '. · .. il1 .SHRs:.:only"~t-~OOO.!fiig/ks(UQ.StiRs,' rilinenidine 
caused signif~cailt requctio~. "in ~s . I: .... a(~9s·es. 300 nig/kfj' ~r# ~ OOQ'riig/kg .. _=However,. in DSHRs 
rilmenidine ·caused significa . edud!on'·in RSNA only at a high' dose'(lOOO .tng/kg). During 
acute volume expansio ere we¥e~fio meaningful changes in the SBP and HR in both groups 
of animals, but the · and RSNA were suppressed. Futhen:nore, there were significant overall 
differences in and RSNA between SHRs and DSHRs. '' 
In su mary, the sympathoinhibitoi-y action of rilmenidine and volume expansion appeared 
to be reduced in diabetic spontaneously. hypertensive rats suggesting that in diabetes, the central 
drive generating t~enal_.sympathetic n'eJV~ aCtivitY. was .resis~aht ·to fegulatiori~by neuraJ pathways 
involving .:puta:tive imadazolin~ .receptor ~activation. 'I · .r ~ · \ · · L. ,:, i 
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KININOGEN.JN J:J;:RM,.fETOPLACENTAL )ISSpES FROM NORMOTENSIVE PREG-
NANT .WOMEN ~AND;;WOI\'IEN \ViTH PREGNANCY-INDUCED HYPERTENSION. 
M Mahan~em/ETLCirmiri,.-'HJ Singh.· Department of Physiology} ~f?.bJ.dol of Medical Sciences} 
Uniuersiti Sains Malaysia} Kelantanl Malaysia. "l:"':·;·.~, 
' . .• . . . ' . . ... ' . . . . . . . .· .. ··. :;.; 
The .path6~~~~sis Sf~p~~~~~~indti~~d .. ·hy~~ffensi~~~:(f,JH.l•};~~As · ~i~~1~ma~~it ·~~ p~stulated 
that imbalar1Ce of: "placental WSOCOQStrictor ?~d .vas~cHJafor substanc¢s may contribute to the 
place~tal hyp9petfusion in P~~. T~~ref<?re ~e o?jec9ve ~~f ·this study ;;.yas··to ·estim~te the l~vels 
of kimnogen, ~_pr~cursor of k~m (a, potent ~sod1la}p~2}, t_n fetoplasent~ homogena!es obtatned 
from normotensive.:_pregnant ~Y.,omen and women ·with PIH. ,f.: .~~j • _} \ .r:· ·, 
A portion of chorion ·Ja.'etle~ ·amniotic· membrane, placenfal.pla'fe·:·cno·riontfetal placenta 
(fetal surface of placenta) and maternal placenta (surfac~. 0f placenta attached to the uterine wall) 
were obtained . .from. 8 nolTilotensive,.pregnC1flt w6m¢n:-?tnd .8. women with pregnancy-induced 
hypertens1on 'after· receiving· informed consent ~Each: tissue was washed thqroughly with Krebs-
Hensleit(KH) buffer, p_H: 7_;9-, Bri~~,,benY~en filter papers, weighed and frozen in buffer solution 
at -20°C until when needed. Tissue homogenate was prepared in re.levant volume of KH buffer 
using a homogenizer. ~fter-centrifugafton, the supernatant was dialyzed overnight at 4°C against 
Tris-HCl buffer, pH·7.4. Kininogen was further trypsinized to generate kinin. The released kinin 
wa·s then estimated by EIA. -Kininogen values were expressed. as pg bradykinin equivalent/mg 
of tissue .. All :esults were present~d as mean_ SEM. Statistical analysis was per,t~rm~p u~.pg a 
non-parametric test, ·Kruskal-Walhs test, and a p value of <0.05 was constg~_req §tgnifi.dmt.· 
Kininogen levels .were significantly (p<O.OS) lower in chorion laeve, amill'Qti~·in~inbrtrne 
pl~centai plate chorion, fetal placenta and maternal placent~ p 14.26±4~.9~;· ~,6%.;~l~:f~,~~g~: 
2ol.82±52.14, 1_56.60±21.37, 122.22±25.7_1 p~ bradykirun Eq/mg tiss~eJ~pe.,s~y~ly)jrbm 
women with PIH compared to the correspondlng tissues from normotensiv~1pr~gn?li:W7tvS'fii~n 
Kininogen levels wer~ found to be significantly lo.w~r in the fetoplacental tiss~es ' 0b{afri~d~fr.O~ 
. women witJ: PIH. ~his rna~ reflect. a decreased kirunoge~ pr~duction and hence ·a···reduction:'in 
kinin forrnahon.··This alteration may therefore_play a role m placental hypoperfusion seen in PIH. 
1. Walsh SW. AM. 'J. .O~~t. ~~c~h152: 3~~340. 
2_ Bhoola KD, Figueroa · an 9 . a~~v. 1992; 44: 1-80. 
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Introduction 
Diabetes is a known risk factor in c ronary heart 
disease. A number of antihyperten ive drugs are 
known to be diabeto·genic. This . ay contribute 
to the less than expected decreas in the incident 
of coronary heart disease with r tluction in blood 
pressure with treatment in hype ensive patients. 
·-Objective 
This study is to determine the ~ffects of a member, 
Valsartan, of a new clas~ of if"UQS, a~giotensi.n.II 
antagonists, on glucose md ed msulm secretion. 
n Department .~f .Physiology1, Department of 
~ _Obstetric lind Gynecology2 , School of Medical 
Sciences, Universiti Sa ins ·M-alaysia, 16150 
~ Kubang Kerian, Kelantan, Malaysia. 
M Introduction 
~ The pathogenesis· of pregnancy-induced 
1 hypertension (PIH) remains an enigma. It is 
c postulated that an imbalance of vasoactive 
a substances -..may contribute to the placental 
1 hypoperfusion in PIH. 
Methodology s Objective·- ... . 
Male albino rat pan ere ses were used. The c To estimate .the.levels of kininogen arid tissue 
isolated pancreases wer. perfused with Kreb's 1 kaUikrein.activity;- the substrate and enzyme that 
solution containing bov· e albumin (200mg/dl) e respo_ns1ble to generate kinin (a potent 
with tow glucose (60 g/dl) followed by high n vasodilator), in fetoplacental tissues obtained 
glucose (300mg/dl) at rate of 4 mls/mins. The ~ from women with normal pregnancy and PIH. 
dose of Valsartan is ba ed on the peak blood level s 
achieved in human at tandard single dose of 1.64 Methodology 
mg/L. Five treatmen groups were used: Control, . A portion of amnion, chorion leave, placental plate 
Valsartan at 10°/c, 100°/o and at 10 times chorion, fetal placenta and maternal placenta 
therapeutic level, nd with Diazoxide 10 ug/ml 1 were obtained from 12 women with normal 
which is known t inhibit approximately 50°/o of 111 pregnancy and 12 women with PIH. Each tissue 
insulin secretion. Insulin levels in the perfusate was washed throughly with Krebs-Henseleit 
were measured · y radioimmunoassay. N buffer, blotted dry, weighed and frozen until used. 
Results 
vatsartan a~p · icularly lower doses, significantly 
increase the lucose induced insulin secretion (P<O.OS). Va sartan at 10 °/o therapeutic lev~l, at 
therapeutic I vel and at 10 times therapeutic level, 
increases ucose induced insulin secretion by 
180olo, 13t Vo and 129°/o respectively. Diazoxide 
as expect d, ~ignificantly inhibit glucose induced 
insulin sl ret1on (P < 0.05). 
conclusion 
Valsartan stimulates glucose induced insulin 
secretion particularly at lower therapeutic levels. 
60 
a Level of kininogen and both active and total tissue ! kallikrein activity~\~ estimated in each tissue. 
0 Results and ConciJ'~ion 
n 
a Kininogen levels were found to be significantly 
1 lower in chorion laev~, placental plate chorion, fetal placenta and maternal placenta in women 
c with PIH. No significant differences were found 
o for active, total and calculated inactive tissue 
n kallikrein activity in various fetoplacental tissues 
t for both groups. However, the overall kininogen/ 
e tissue kallikrein ratio, which reflects the overall 
r kinin production in whole fetoplacental unit was 
e found to be significantly lower m women with PIH. 
n In addition, there was a negative correlation 
~ between this ratio to maternal diastolic blood 
presuure. These findings may therefore confirm 
0 the reported preponderance of vasoconstrictor 
n substance~ th.at might account for placental 
hypoperfus1on m PIH. 
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ABSTRACT 
.. 
. . 
The pathogenesis·~ of pregnancy-induced ···hypertension·· (Pil-l) remains an 
enigma. However, it is currently postulated that placental hypoperfusion due 
to an imbalance of vasoconstrictor and vasodilator substances in the placenta 
may contribute to the pathogenesis of PIH. Hence, the objectives of this study 
are: (1) to determine the kininogen {using enzyme immunoassay) and tissue 
kallikrein levels (using a synthetic chromogenic substrate, S-2266), the 
substrate and enzyme, respectively, that are responsible for the generation of 
kinin (a vasodilator); (2) to determine the molecular weight of tissue kallikrein 
(by Western blot analysis); and (3) to determine the gross effect of 
fetoplacental tissue extracts on the contraction of rabbit jejunum smooth 
muscle using various fetoplacental tissues from 12 normotensive pregnant 
women and 12 women with PIH. No significant differences were found for 
active, total and inactive tissue kallikrein levels in tissues from both groups. 
However, kininogen levels and kininogen/total tissue kallikrein ratios were 
significantly lower in chorion laeve, placental plate chorion, fetal placenta and 
maternal placenta from women with PIH. The molecular weight of tissue 
kallikrein was about 52 kDa for both groups. These findings might indicate a 
lower level of kinin generation in fetoplacental tissues of women with PIH 
confirming the reported preponderance of vasoconstrictor activity. The higher 
increase in smooth muscle tone produced by application of the fetoplacental 
tissue extracts from women with PIH also further supports this postulate. 
SISTEM KALLIKREIN-KININ Dl DALAM TISU FETOPLASENTA YANG 
DIPEROLEHI DARIPAPA WANITA YANG MENGHIDAP HIPERTENSI 
AKIBAT KEHAMILAN (ABSTRAK) 
Patogene~is hipertensi akibat kehamilan (HAK) masih betum diketahui. Walau 
bagaimanapun, kini ia dipostulat bahawa hipoperfusi plasenta akibat 
ketidakseimbangan bahan vasokonstriktor dan vasodilator mungkin 
menyumbang kepada patogenesis HAK. Oleh itu, objektif kajian adalah: 
(1)menentukan aras kininogen (menggunakan imunoesei enzim) dan tisu 
kallikrein {menggunakan substrat kromogenik sintetik, S-2266), substrat dan 
enzim, masing-masing, yang bertanggungjawab menghasilkan kinin {satu 
vasodilator); (2)menentukan berat molekul tisu kallikrein (menggunakan analisis 
blot Western); dan (3)menentukan secara kasar kesan ekstrak tisu fetoplasenta 
ke atas kontraksi otot licin jejunum arnab dengan menggunakan beberapa tisu 
fetoplasenta daripada 12 wanita hamil yang normal dan 12 wanita yang 
menghidap HAK. Tiada perbezaan yang signifrkan didapati bagi aras tisu 
kallikrein aktif, total dan inaktif di dalam tisu dari kedua-dua kumpulan. 
Walaubagaimanapun, aras kininogen dan nisbah kininogen/tisu kallikrein total 
adalah lebih rendah secara signifikan di dalam korion laeve, korion plat 
plasenta, fetal plasenta dan maternal plasenta dari wanita yang menghidap 
HAK. Berat molekul tisu kallikrein untuk kedua-dua kumpulan adalah lebih 
kurang 52 kDa. Penemuan ini mencadangkan penghasilan kinin yang lebih 
rendah di dalam tisu fetoplasenta wanita yang menghidap HAK selaras dengan 
laporan mengenai aktiviti vasokonstriktor yang tebih tinggi. Peningkatan tonus 
otot ticin yang dihasitkan metalui aplikasi ekstrak tisu fetoplasenta daripada 
wanita yang mengidap HAK menguatkan lagi sokongan terhadap postulat 
tersebut. 
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1. INTRODUCTION : 
Hypertensive disorders· of pregnancy have· been reported to ~complicate almost 
10% of all ·:·pregnancies (Gifford ef a/, 1990). ·Among· these disorders is 
pregnancy-induced hype~ension (PI H), which refers to· both gestational 
hypertension and preeclampsia {Davey & MacGillivary, 1988). PIH not only 
predisposes mothers to severe complications such as abruptio placenta, 
cerebrovascular accident, end-organ failure, disseminated intravascular 
coagulation and death but also predisposes fetuses to intrauterine growth 
retardation, intrauterine death and iatrogenic preterm delivery (Gifford et.a/, 
1990). 
Despite the serious impact of PIH on maternal and fetal health, research into its 
pathogenesis still remains an enigma. It is presently believed that the placenta 
plays a central role in the pathogenesis of PIH. This is eyidenced by the fact 
that delivery of the placenta or termination of the pregnancy seems to be the 
only definitive cure for this condition. The clinical· manifestations have been 
attributed to a reduced uteroplacental perfusion (Trudinger et.a/, 1985). It is 
presumed that the ischaemic placenta then releases a stress factor( s) into the 
maternal circulation that cause(s) a generalized maternal endothelial 
dysfunction resulting in multiple pathophysiological changes and the 
subsequent clinical manifestations of PIH (Baker et.al, 1995 & Brockelsby et.a/, 
2000). 
Defective placentation has been postulated to cause placental hypoperfusion in 
PIH (Sheppard & Bonnar, 1981 & Khong et.al, 1986). A number of postulates 
3 
.have been proposed ·tQ ~xplain the possible; cause(s) for the defective 
placentation. These include: a genetic predispositon (Cooper· et.al, 1988 · & 
. Lachmeijer et.al,~· 1998),- an immune maladaptation (Campbell et.a/, 1985 & 
Colbern et.a/, 1994) and an intrinsic defect of the trophoblastic·function (Zhou 
et.al, 1997). 
Another plausible cause proposed for the placental hypoperfusion is an 
imbalance of vasodilator and vasoconstrictor substances. This possibility is 
attributed to the fact that placenta ha~ no neural innervation (Reilly & Russell, 
1977 & Khong et.a/, 1997), hence, it is plausible that regulation of placental 
circulation may be due mainly to the action of inherent vasoactive substances. 
Thus, a higher level of vasoconstrictor substances over vasodilator substances 
within the placenta may cause vasospasm and subsequent placental 
hypoperfusion. This possibility is borne on one hand by the fact that the levels 
of vasoconstrictors such as endothelin-1 (Singh et.a/, 2001) and thromboxane 
(Walsh, 1985) have been reported to be higher in placentas obtained from 
women with PIH as compared to those in normal pregnancy. On the other hand, 
the levels of vasodilator such as prostacyclin (Walsh, 1985) and nitric oxide 
synthase, enzyme for the production of another vasodilator, nitric oxide 
(Brennecke et.al, 1997), have also been reported to be lower. It is also possible 
that an imbalance of vasoactive substances within the placenta during early 
stages of gestation may precipitate placental hypoxia that may also result in 
defective placentation (Genbacev et.al, 1996). However, to date, no data is 
available on the level of placental· kinin (another potent vasodilator) or its 
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components kininogen -~nd tissue. kallikrein that form the kal1ikrein-kinin .system 
(KKS) in pl~cental tissues of women ~ith· PI H. ·. - · 
. ~· . . ·, .. 
The presence of kininogen (Hermann et.a/, 1996), tissue kallikrein (Valdes et.a/, 
2001a) and kinin 82 receptors (Valdes et.a/, 2001b) have been reported in 
normal human fetoplacental tissues. This indicates that kinin is produced locally 
in the placenta and therefore might also play a role in the regulatio~ of the 
placental blood flow. Kinin has a very short half-life for it to be measured 
directly, therefore, in this study the level of kinin is indirectly estimated by the 
determination of the levels of kininogen and tissue kallikrein, . the substrate and 
enzyme respectively, that are responsible for the production of kinin in tissues. 
2. OBJECTIVES 
1. To determine the levels of kininogen in various fetoplacental tissues 
obtained from normotensive pregnant women and women with PI H. 
2. To determine the levels of active, total and inactive tissue kallikrein in 
various fetoplacental tissues obtained from both groups. 
3. To determine the molecular weight of tissue kallikrein in the various 
fetoplacental tissues obtained from both group since this has hitherto not 
been determined and to see any differences between the groups. 
4. To determine the gross effect of fetoplacental extracts, obtained from both 
groups, on smooth muscle tone to test the hypothesis of an imbalance of 
vasoactive substances in the placenta. 
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3. METHODS A.ND MA\TERIALS 
; . d I.. : • ;. i 
3.1 Subject selectiQn 
~ 
-- ---::-.--~-' -------·---------~-- ---T. 
' ·'~'" :-:. . . -· .... . 
- --·--- ·-· -~----- ~~' --·-----· ---·-·. - -------
After receiving· an . infOrmed .consent, .fresh_ placentas were. obtained·. from 1.2 
--- ·.' .... ·--
normotensive pregnant (NP) women and 12 women with pregnancy-induced 
hypertension (PIH). For women with PIH, the inclusion criteria included: a 
diastolic blood pressure of ~ 11 OmmHg on one occasion or ~ 90mmHg on two 
occasions, taken at least four hours apart, that developed after 20 weeks of 
gestation with the presence or absence of proteinuria, and a return of the blood 
pressure and abnormal urine to normal values within 6 weeks after delivery 
(Davey & MacGillivray, 1988 & Brown et.al, 2001). The exclusion criteria 
included: age above 40 years, delivery before third trimester of pregnancy, 
presence of hypertension or proteinuria before pregnancy or before 20 weeks of 
gestation, presence of underlying diabetes mellitus, renal disease or hepatitis 
and multiple pregnancies. Controls consisted of NP women with no medical 
illnesses. All subjects were matched for race, maternal age and gestational age. 
Data consisting of maternal age, gestational age at sampling, systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) before delivery and 
neonatal birth weight were recorded. 
3.2 Preparation of fetoplacental tissues 
Portions of amnion, chorion laeve, placental plate chorion, fetal placenta (fetal 
surface of placenta) and maternal placenta (surface of placenta attached to the 
uterus) were dissected from each placenta as described by Singh et.a/ {2001) 
(Figure 3.1). Each tissue was theh placed in a plastic test tube containing 
Krebs-Henseleit (KH) buffer (Appendix A). It was immediately transported to the 
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Placenta and its membranes Amnion 
Chorion laeve Placental plate chorion 
Fetal placenta Maternal p_lacenta 
Figure 3.1: Photographs showing dissected portions of amnion, chorion laeve, 
placental plate chorion, fetal placenta and maternal placenta from a placenta 
and its membranes. 
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laboratpry where each of the tissue was put :on separate plastic petri dishes and 
washed thoroughly by :renewing the· buffer severat·times to remove the"·blood . 
. -Subsequently the tissues were dried between filter papers, weighed and frozen 
in KH buffer at -sooc for analysis at a later date (Singh et. a/, 2001 & Sharma 
et.al, 1998). 
3.3 Preparation of samples from various fetoplacental tissues for 
determination of kininogen and tissue kallikrein levels 
Preparation of samples for kininogen and tissue kallikrein levels determination 
was done as described by Sharma et.al (1998). Each tissue was separately 
homogenized in the relevant volume of KH buffer (200mg tissue/ml buffer) with 
a homogenizer (IKA Labortechnique, Germany). After centrifugation at 3000rpm 
for 1 0 minutes at 4°C, the supernatant was dialyzed overnight at 4°C against 
0.01M Tris-HCI buffer, pH 7.4 (Appendix B) in a beaker, that contained a 
magnetic bar and was placed on a magnetic stirrer. The dialyzed supernatant 
was used as a sample for further assays. 
3.4 Determination of kininogen level in each sample 
Kininogen level in each sample was determined by trypsinizing the sample to 
generate kinin as in 3.4.1. The released kinin was estimated by enzyme 
immunoassay (competitive binding technique) using Markit-M Bradykinin kit 
(Dainippon Pharmaceutical Co., Ltd, Japan) (Sharma et.al, 1998) (Figure 3.2). 
The released kinin in the sample and the peroxidase-labeled bradykinin were 
allowed to react ·competitively with rabbit anti-bradykinin antibody, which was 
captured by goat anti-rabbit lgG antibody coated on each micros trip well. The 
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kinin concentration was determined from the enzyme activity of peroxidase-
labeled bradykinin bound to anti-bradykinin antibody. The kininogen value was 
expressed as bradykinin equivalent/rng of tissue. The specificity of Markit-M 
Bradykinin to bradykinin and lys-bradykinin (kallidin) was 100%. 
3.4.1 Preparation of a pre-treated sample 
Preparation of a pre-treated sample was done as follows: 
1. Each sample was diluted in deionized water (1 :5 dilution). 
2. 1 ml of diluted sample in a test tube was boiled in a water bath for 1 0 minutes 
(100°C). This was allowed to cool and then incubated with 20JJ.g trypsin, 
TPCK (Sigma, USA) for 60 minutes at 37°C, in the presence of 3mM 1-10 
phenanthroline (Sigma, USA; Appendix C). 
3. The reaction was stopped by adding 1 OOJJ.Q of soybean trypsin inhibitor 
(SBTI; Sigma, USA) for 20 minutes and then boiled in a water bath for 2 
minutes. 
4. Then O.Sml of sample was treated with 0.1 ml 20o/o trichloroacetic acid (a 
deproteinizing agent; from the kit), mixed and centrifuged at 3000rpm for 1 0 
minutes at 4°C. 
s. 0.25ml of supernatant was added to 0.25ml Buffer B (from the kit) and ready 
as a pre-treated sample. 
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I • Add 1 OOJ..tl of bradykinin antibody to each well 
~· l . . , ' ~ Incubate at room temperature for 1 hour 
Wash 3 times with 300J..tl wash buffer solution 
t-:; ·f. 
( 1) Add 1 OOJ..tl of buffer solution C and SOJ.LI of each standard solution to the 
standard well 
(2) Add 50J.LI of buffer solution A and 1 OOJ..tl of each pre-treated sample to the 
sample well 
l Mix & incubate at room temperature for 1 hour 
Add 50J.LI of bradykinin enzyme conjugate into each well l Allow to stand overnight at 4 oc 
Remove the content and wash each well with 300J..tl wash buffer for 4 times 
l Put the plate upside down & tap on a paper towel 
Add 1 OOJ.LI of substrate solution to each well 
Allow to stand at room 
temperature for 30minutes 
Add 1 OOf.ll of stop reagent 
l Mix & incubate at room temperature for 30 minutes 
Measure the absorbance at 490nm wavelength with a microplate reader 
Figure 3.2: Flow chart showing assay procedure to determine the kininogen 
level using Markit-M Bradykinin kit. 
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3.5 Oetermination of tissue kallikrein level in each sample 
Tissue kallikrein level was determined by the activity of tissue kallikrein on a 
synthetic .chromogenic substrate, H-0-Vai-Leu-Arg-pNa (S-2266; Chromogenix 
Instrumentation Laboratory SpA, Italy), which was specific for tissue kallikrein. 
Tissue kallikrein hydrolysed this substrate and the rate of paranitroaniline (pNA) 
formation, which was proportional to the tissue kallikrein level in each sample, 
was measured using a spectrophotometer (JASCO, Japan) (Sharma et.a/, 
1998). 
The time interval during which the rate of paranitroaniline formation increases 
linearly with the increasing concentration of tissue kallikrein for the purified 
tissue kallikrein activity on the substrate was determined. The upper limit of this 
time interval was taken as an optimum time for tissue kallikrein activity. This 
optimum time was then used to prepare a standard graph for tissue kallikrein. 
The enzyme level in each sample was obtained from this standard graph and 
then calculated as kallikrein unit in 1 mg tissue (ku/mg). One kallikrein unit (ku) 
hydrolyzed 1.0J..LmOI of S-2266 to paranitroaniline (pNA) per minute (Sharma 
et.al, 1998). 
3.5.1 Determination of the optimum time for purified tissue kallikrein 
activity 
The determination of the optimum time for purified tissue kallikrein activity was 
done as follows using 60ku/ml of porcine pancreatic tissue kallikrein (Sigma, 
USA) (Appendix ·o): 
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1. 2250JJ.I of 0.05M, pH 9.0 Tris HCI (Appendix E) was incubated at 37°C in a 
sterile plastic tube. 
2. After 5 minutes, 50J..LI of 60ku/ml purified tissue kallikrein was added, mixed 
well and incubated for 2 minutes at 37°C. 
3. Then 200J.1I of 2mM S-2266 was added (Appendix F) an~ mixed well for it to 
be hydrolyzed by tissue kallikrein. (Blank solution was also prepared by 
using the same reagents as above in the same order but substituting 200J..LI 
of Tris HCI buffer for the substrate S-2266 solution) 
4. The absorbances for purified tissue kallikrein activity at 0.5, 1, 2, 3, 4, 5, 6, 7, 
8, 9 and 1 0 minutes were obtained using a spectrophotometer at a 
wavelength of 405nm. 
5. The results obtained are the mean values of triple determinations. A graph 
of the absorbance of 60ku/ml purified tissue kallikrein activity (A) against 
time (minute) was plotted (Figure 3.3). 
6. Using the linear portion of this graph, another three graphs of the 
absorbance of 60ku/ml purified tissue kallikrein against the times of o to 3 
minutes, 0 to 4 minutes and 0 to 5 minutes were plotted (Figure 3.4, 3.5 & 
3.6, respectively). Among these graphs, the graph obtained for o to 4 
minutes was found to be the most linear graph with the highest correlation (r 
= 0.996 and A/min= 0.12; Figure 3.5) (Sharma et.al, 1998). 
7. Hence, four minutes was chosen as the optimum time for tissue kallikrein 
activity (i.e. the rate of paranitroaniline formation increases linearly with the 
increasing concentration of kallikrein up to 4 minutes). It was then used to 
prepare the standard graph for tissue kallikrein level and also to determine 
the tissue kallikrein level in each sample. 
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Figure 3.3: The absorbance of 60ku/ml purified tissue kallikrein activity against 
time. 
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the time of 0 to 5 minutes. 
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3.5.2. : Preparation- of a standard graph for tissue kallikrein level · ; 
. A standard graph ·for tissue kallikrein· level using purified tissue kallikrein at 
- different· concentration~ (from .o to 1 Oku/ml) was prepared ·(Appendix ·G). This · 
wide range of concentration was chosen since no data is available to quantify 
the tissue kallikrein level in fetoplacental tissue. Preparation of this standard 
graph was done as follows: 
1. 2250J.tl of Tris HCI buffer pH 9.0, O.OSM was preincubated at 37°C in a 
sterile plastic tube. 
2. After 5 minutes, SOfJ.I of Oku/ml purified tissue kallikrein was added, mixed 
well and incubated for 2 minutes at 37°C. 
3. Then 2001J.I of S-2266 was added, mixed well and incubated. (Blank solution 
was also prepared by using the same reagents as above in the same order 
but substituting 2001J.I of Tris HCI buffer for the substrate S-2266 solution) 
4. At four minutes, after adding S-2266, the absorbance for purified tissue 
kallikrein activity was measured using a spectrophotometer at a wavelength 
of405nm. 
5. These steps were repeated using different concentrations of purified tissue 
kallikrein (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, and 1 Oku/ml). 
6. The results presented are the mean values of triple determinations. A 
standard graph was plotted with different concentrations of standard tissue 
kallikrein on the X-axis (ku/ml) and the absorbance on Y-axis (00). 
3.5.3 Determination of active tissue kallikreun level in each sample 
Active tissue kallikrein level in each sample was determined as follows: 
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1 .. 22501J.I of Tris HCI buffer pH 9.0, 0.05M was preincubated at 37°C ·in plastic. 
sterile test tubes .. 
2.- After 5 minutes,,501J.I of.each sample was added, mixed well and~incubated 
for 2 minutes at 37°C. 
3. Then 200JJ.I of 2mM S-2266 was added and well mixed. (Blank solution was 
also prepared by using the same reagents as above in the same order but 
substituting 200J.LI of Tris HCI buffer for the substrate S-2266 solution) 
4. At four minutes, after adding S-2266, the absorbance for tissue kallikrein 
activity in each sample was measured using a spectrophotometer at a 
wavelength of 405 nm. 
5. The results presented are the mean values of double determinations. The 
active tissue kallikrein level in each sample was obtained from the standard 
graph and then calculated as kallikrein unit in 1 mg fetoplacental tissue 
(ku/mg). 
3.5.4 Determination of total tissue kallikrein level in each sample 
Total tissue kallikrein level in each sample was determined by trypsinizing the 
sample to activate the inactive tissue kallikrein that might be present in the 
sample and followed by the steps in 3.5.3 as above. These were done as 
follows (Sharma et.al, 1998): 
1. Trypsinized sample was prepared by adding 20J.LQ of trypsin, TPCK (Sigma, 
USA; Appendix H) to 500J.tl of sample. This was well mixed and incubated at 
, 
2. After 30 minutes, 1 OOJ.!Q of SBTI (Sigma, USA} was added to stop the 
reaction. 
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.3.- Then 50J,.tl of trypsin~zed sample was added to 2250J.l.l of :~keincubated · Ttis 
HCI buffer.:pH-9.0·, O;OSM at 37°C for 15 minutes. This again:· was· mixed well 
and incubated again at 37°C for 2 minutes. · )· · 
4. This.was followed by the addition of 200J.l.l of 2mM S-2266, which was mixed 
well and then incubated at 37°C. (Blank solution was also prepared by using 
the same reagents as above in the same order but substituting 500).l.l of Tris 
HCI, 50).l.l of trypsinized Tris HCI and 200).l.l of Tris HCI buffer for the sample, 
trypsinized sample and S-2266 solution, respectively) 
5. At 4 minutes, after adding S-2266, the absorbance for total tissue kallikrein 
activity in each sample was measured using a spectrophotometer at a 
wavelength of 405nm. 
6. The results presented are the mean values of double determinations. The 
total tissue kallikrein level in each sample was obtained from the standard 
graph and then calculated as kallikrein unit in 1 mg fetoplacental tissue 
(ku/mg). 
3.5.5 Calculation of inactive tissue kallikrein level in each sample 
The difference between total and active tissue kallikrein was calculated as 
inslctive tissue kallikrein level in each corresponding sample. The results were 
expressed as kallikrein unit in 1 mg fetoplacental tissue (ku/mg). 
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3.6 . l!>etermination of the molecular weight of tissue kallikrei~ Jn each ~ 
sample of ·the various fetoplacental tissues obtained -from both 
groups using Western blot analysis 
The molecular weight of tissue kallikrein was first determined in the samples of 
maternal placenta obtained from NP women. This was then followed by 
determination of tissue kallikrein in the samples of various fetoplacental tissues 
to see any differences between the two groups. The samples were prepared as 
steps in 3. 3 except that the volume of KH solution added to each fetop1acental 
tissue was 1 ml for a 400mg of tissue. The samples and standard protein 
(purified human urinary tissue kallikrein - Calbiochem®, Germany) were then 
separately loaded onto sodium dodecylsulfate (SDS) polyacrylamide gel 
followed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), using Mini-
Protean II Cell (Bio-Rad, USA), to separate the proteins based on their 
molecular size. The separated proteins were then electrophoretically transferred 
to a nitrocellulose paper, using Mini-Transblot Electrophoretic Transfer Cell 
. (Bio-Rad, USA). The paper was then incub~ted in a first antibody followed by a 
second antibody. The second antibody was then visualized by a precipitable 
substrate (Weerasinghe & Gadsby, 1992 & Hermann et.al, 1996 with some 
modifications, Figure 3. 7). 
3.6.1 Preparation of !;'Odium dodecylsulfate (SDS)-polyacrylamide gel 
The 50S-polyacrylamide gel was prepared as follows: 
1. Glass plate sandwich, using 2 clean glass plates & 2 spacers, were 
prepared. 
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2. 1 The sandwich was locked to the casting stand (leaking was ~··checked with 
·deionized water).- .. ~ • - ~ '- ' -lA • .. •• _., - ... - ' -c.·- • 
3. A separating gel solution (7.5%) was prepared ·in a flask (Appendix I) and 
transferred to the center of the sandwich. 
4. A layer of deionized water (about 1cm thick) was pipetted slowly to cover the 
top of the resolving gel to make the upper level smooth. It was allowed to 
polymerize for 15 minutes at room temperature. 
5. Then the layer of deionized water was poured off completely. 
6. A stacking get solution (4o/o) was prepared (Appendix J) in a flask. 
7. The stacking gel solution was pipetted onto the resolving gel followed by the 
insertion of a Teflon comb (with 10 welts) into it. 
8. Additional stacking gel solution was added to completely fill the spaces in 
the comb. 
9. The solution was allowed to polymerize for 15 minutes at room temperature. 
3.6.2 Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was done as follows: 
1. 4 protein samples were prepared as follows: 
a) 1 OJ.tl standard protein (human urinary tissue kallikrein- 3.1 J..lg) 
b) 1 OJ.tl sample (from maternal placenta - 4mg) 
c) 1 OJ.!I standard protein and 1 Oo/o 2-mercaptoethanol (Bio-Rad, USA) 
d) 1 OJ! I sample and 1 Oo/o 2-mercaptoethanol 
Each protein sample was diluted separately in 1 o,....l electrophoresis sample 
buffer (Appendix K) and 0.005g bromophenol blue (FisherChemical, USA). 
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(Sample and standard pr0tein without 2-mercaptoethanol were?also used ir:t 
this study to ·see if any; tissue kallikrein subunit ,might be present. in -each · 
solution as described by Weerasinghe & Gadsby, 1992). 
2. All samples were boil separately for 1 0 minutes at 1 oooc and then 
centrifuged at 120rpm for 5 minutes. 
3. The Teflon comb was removed carefully & the bubbles were flushed with 
deionized water. 
4. The sandwich was placed into the buffer chamber. 
5. A liter of running buffer (Appendix L) was poured into the lower & upper 
chamber till the sample wells of the stacking gel were filled with the buffer. 
6. 1 OIJ.I aliquot of each protein sample was separately loaded with a Hamilton 
syringe into the bottom of each well. This was done in duplications. 
7. Then 5J.tl molecular weight marker (Gibco-BRL, USA) was loaded into 2 
most lateral wells. 
8. The gel was run for 1 hour at 0.25Amp. of current. 
9. The sandwich was removed from the chamber and one glass plate was 
opened carefully. 
10. The stacking gel was removed. 
11. The separating gel was then cut into two portions with one portion preserved 
for staining and the other for transblotting. 
12. The staining of the gel was done with Cosmassie Blue solution (Appendix M) 
for 1 hour followed by destaining in a destaining solution (Appendix N) for 
subsequent photograph and kept as a permanent record. 
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3.6.3 Trans blotting to nitrocellulose membrane · ·.i 
1~ The other portion of .gel (as prepared. in 3~6 . .2):was placed into~ container 
filled with running buffer. 
2. Prewetted (i.e. with running buffer) Scotch-Brite pad was put on the plastic 
support (black for cathode). 
3. A Whatman filter paper was put under the gel, which was in the plastic 
container filled with running buffer. Then the gel, with Whatman filter paper 
under it, was placed onto the previously prewetted Scotch-Brite pad. 
4. A prewetted (i.e. with running buffer) nitrocellulose membrane was placed 
directly on the gel. All air bubbles were removed with a glass rod. 
5. Another prewetted Whatman filter paper was placed on the nitrocellulose 
membrane and all air bubbles were again removed. 
6. Then, another prewetted Scotch-Brite pad was placed on top of this 
Whatman filter paper to support both gel and nitrocellulose membrane. 
7. The plastic support was closed and placed into the electroblotting apparatus 
in the correct orientation (black for cathode & white for anode). 
a. The tank was filled with transferring buffer (Appendix 0). 
9. The proteins in the gel were transferred at 0.25Amp. of current for 1 hour at 
4°C. 
1 o. After complete transfer, the nitrocellulose membrane was placed in Ponceau 
s solution (Appendix P) for 5 minutes to stain the proteins. 
11. Then it was destained in deionized water for a few times, the molecular 
weight of the standard marker band was marked and the marker lane was 
cut. 
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12. The. other portion of nitrocellulose memlorane was. then placed in.· blocking 
· solution (Appendi~· Gl} to block non-specific antibody sites on the membrane 
for 1 hour. 
13. Then it was washed with deionized water for 3 times. 
14. The membrane was then incubated in 1:2000 dilution of rabbit anti-human 
urinary tissue kallikrein (as primary antibody; Calbiochem®, Germany) in 
phosphate buffer saline (PBS) solution {Appendix R) for overnight. 
15. Then it was washed with Tween-20 solution (Appendix S) 6 times every 10 
minutes. 
16. This was followed by incubation with 1 :5000 dilution of Horseradish 
peroxidase-conjugated goat anti-rabbit lg-G (as secondary antibody; 
Calbiochem®, Germany) in PBS solution for 1 hour and was covered with 
aluminium foil. 
17. Then, it was washed with Tween-20 solution for 6 times every 10 minutes. 
18. The membrane "vas then incubated in 4-chloro-naphtol substrate solution 
(Appendix T) for 15 minutes and covered with aluminium foil. 
19. The staining reaction was then stopped by washing with deionized water 
twice. The stained membrane was photographed and kept as a permanent 
record. 
The molecular weight of tissue kallikrein in each sample (i.e. amnion, chorion 
laeve, placental plate chorion, fetal placenta and maternal placenta) obtained 
from both groups was determined using the same steps as in 3.6.2 and 3.6.3. 
All samples were prepared in the presence of 2-mercaptoethanol in order to 
determine the molecular weight of tissue kallikrein in each sample. 
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